ZGN-1061
Names | |
---|---|
Preferred IUPAC name
[(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] 3-(2-morpholin-4-ylethyl)azetidine-1-carboxylate | |
Other names
ZGN-1061, Aclimostat
| |
Identifiers | |
3D model (
JSmol ) |
|
ChEMBL | |
ChemSpider | |
DrugBank | |
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C26H42N2O6 | |
Molar mass | 478.630 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
ZGN-1061 is an experimental drug that was developed by Zafgen for treatment of obesity and type 2 diabetes. It has a similar mechanism of action as the discontinued drug Beloranib but was considered safer; however, its development was also halted because of safety concerns.[1][2][3]